Arthritis, Psoriatic News and Research

RSS
Immune-mediated inflammatory disease may increase risk of severe COVID-19 outcomes

Immune-mediated inflammatory disease may increase risk of severe COVID-19 outcomes

New clinical trial to test third dose of COVID-19 vaccine for immunocompromised people

New clinical trial to test third dose of COVID-19 vaccine for immunocompromised people

Exploring young people’s perspectives on patient-reported outcome measures in inflammatory arthritis

Exploring young people’s perspectives on patient-reported outcome measures in inflammatory arthritis

People taking anti-inflammatory drug mount a weaker immune response to COVID-19 vaccine

People taking anti-inflammatory drug mount a weaker immune response to COVID-19 vaccine

Researchers launch clinical trial to assess therapeutic drug monitoring for patients with inflammatory diseases

Researchers launch clinical trial to assess therapeutic drug monitoring for patients with inflammatory diseases

High-resolution TB-PET/CT scanner reveals complete picture of systemic inflammatory arthritis

High-resolution TB-PET/CT scanner reveals complete picture of systemic inflammatory arthritis

Research project moves one step closer to personalized treatment of rheumatic diseases

Research project moves one step closer to personalized treatment of rheumatic diseases

Price check on drug ads: Would revealing costs help patients control spending?

Price check on drug ads: Would revealing costs help patients control spending?

Researchers discover link between rheumatoid arthritis and bacteria in milk

Researchers discover link between rheumatoid arthritis and bacteria in milk

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

Covagen begins COVA322 Phase Ib/IIa study to treat patients with rheumatoid and psoriatic arthritis

Covagen begins COVA322 Phase Ib/IIa study to treat patients with rheumatoid and psoriatic arthritis

Anti-tumor necrosis factor drugs modestly reduce risk of acute coronary syndrome

Anti-tumor necrosis factor drugs modestly reduce risk of acute coronary syndrome

Simponi injection gets FDA approval to treat adults with ulcerative colitis

Simponi injection gets FDA approval to treat adults with ulcerative colitis

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

HealthWell Foundation introduces new lupus fund

HealthWell Foundation introduces new lupus fund

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Important updates on spondyloarthritis highlighted at 2010 SPARTAN meeting

Important updates on spondyloarthritis highlighted at 2010 SPARTAN meeting

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion